Connelly Robert 4

What Happened

• Robert Connelly, CEO, President and Director of Elicio Therapeutics (ELTX), was granted equity awards on February 2, 2026: 73,600 restricted stock units (RSUs) and a 147,200‑share derivative award (stock options). Both awards show an acquisition price of $0.00 (no cash paid) and a reported value of $0 on the Form 4 for the grant date.
• These are compensation awards (not open‑market purchases or sales) and therefore are routine equity compensation rather than an investment purchase. RSUs convert to one share per RSU when they vest; the derivative award is a stock option award that vests over time.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
• Awards: 73,600 RSUs (F1) and 147,200 derivative securities (stock options) (F2); reported price $0.00.
• Vesting (per footnotes): RSUs—25% vest on Feb 2, 2027, then annual installments over the next three years; Options—25% vests on Feb 2, 2027, then the remainder vests in monthly installments over the following three years. All vesting is subject to continued service.
• Shares owned after the transaction: not specified in the excerpt of the filing provided.
• No 10b5-1, tax‑withholding sale, or late‑filing flags noted in this filing excerpt.

Context

• RSUs provide the right to receive one share per unit upon vesting; options give the right to purchase shares subject to an exercise price and vesting schedule (this filing shows the grant and vesting terms but not exercise prices or post‑exercise actions).
• These types of grants are common forms of executive compensation and do not, by themselves, indicate buying or selling sentiment in the market.